AMARIN CORPORATION PLC

Matthew Budoff, MD, discusses the rising prevalence of obesity in type 1 diabetes (T1D) and its cardiovascular implications, emphasizing the need for a treatment paradigm shift to address obesity and cardiometabolic complications. New therapies like SGLT 1/2 inhibitors and GLP-1 receptor agonists show promise, with GLP-1 agonists offering significant benefits in weight reduction and cardiovascular risk mitigation. Early use of calcium scoring or CT angiography is recommended to identify subclinical atherosclerosis. Budoff highlights GLP-1 receptor agonists as a game-changing therapeutic class addressing obesity, diabetes, and cardiovascular health.

The neurodegenerative disorder therapeutics market is projected to grow from $18.53 billion in 2023 to $28.33 billion in 2028 at a CAGR of 9.0%, driven by factors like aging population, rising prevalence of neurodegenerative disorders, and strategic collaborations among pharmaceutical companies.

Deepak Bhatt, a prominent cardiologist, discussed common pitfalls in interpreting clinical trial data at the ESC Congress 2024. His work, cited over 275,000 times, focuses on pivotal trials like REDUCE-IT and SCORED. Bhatt highlighted the 17-year lag between scientific discovery and its adoption into clinical practice.